Relaxin, a pleiotropic vasodilator for the treatment of heart failure

被引：0

作者：

Sam L. Teichman

Elaine Unemori

Thomas Dschietzig

Kirk Conrad

Adriaan A. Voors

John R. Teerlink

G. Michael Felker

Marco Metra

Gad Cotter

机构：

[1] Corthera Inc.,Department of Cardiology and Angiology

[2] Charité Hospital – University Medicine,Department of Physiology and Functional Genomics

[3] University of Florida College of Medicine,Department of Cardiology, Thoraxcenter

[4] University Medical Center Groningen,Section of Cardiology, Veterans Affairs Medical Center

[5] University of California,Department of Cardiology

[6] Duke Clinical Research Institute,Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine

[7] University of Brescia,undefined

[8] Momentum Research Inc.,undefined

来源：

Heart Failure Reviews | 2009年 / 14卷

关键词：

Relaxin; Acute heart failure; Vasodilator; Hemodynamic; Renovascular;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Relaxin is a naturally occurring peptide hormone that plays a central role in the hemodynamic and renovascular adaptive changes that occur during pregnancy. Triggering similar changes could potentially be beneficial in the treatment of patients with heart failure. The effects of relaxin include the production of nitric oxide, inhibition of endothelin, inhibition of angiotensin II, production of VEGF, and production of matrix metalloproteinases. These effects lead to systemic and renal vasodilation, increased arterial compliance, and other vascular changes. The recognition of this has led to the study of relaxin for the treatment of heart failure. An initial pilot study has shown favorable hemodynamic effects in patients with heart failure, including reduction in ventricular filling pressures and increased cardiac output. The ongoing RELAX-AHF clinical program is designed to evaluate the effects of relaxin on the symptoms and outcomes in a large group of patients admitted to hospital for acute heart failure. This review will summarize both the biology of relaxin and the data supporting its potential efficacy in human heart failure.

引用

页码：321 / 329

页数：8

共 118 条

[41] Richter C(2008)Identification of specific relaxin-binding cells in the human female Crit Care Med 36 S75-S88
[42] Dschietzig T(1989)Acute decompensated heart failure and the cardiorenal syndrome Proc Soc Exp Biol Med 190 254-259
[43] Richter C(2007)Blunted responses to vasoconstrictors in mesenteric vasculature but not in portal vein of spontaneously hypertensive rats treated with relaxin Eur J Heart Fail 9 178-183
[44] Dschietzig T(2003)Acute heart failure associated with high admission blood pressure—A distinct vascular disorder? Mol Endocrinol (Baltimore, Md) 17 1075-1084
[45] Bartsch C(2002)Phosphoinositide 3-Kinase activity is required for biphasic stimulation of cyclic AMP by relaxin Am J Physiol Regul Integr Comp Physiol 283 R349-R355
[46] Dschietzig T(2006)Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats FASEB J 20 2352-2362
[47] Bartsch C(1998)Evidence for local relaxin ligand-receptor expression and function in arteries Endocrinology 139 1208-1212
[48] Fevold HL(2002)Demonstration of a relaxin receptor and relaxin-stimulated tyrosine phosphorylation in human lower uterine segment fibroblasts Biol Reprod 66 1743-1748
[49] Hisaw FL(2004)Relaxin gene and protein expression and its regulation of procollagenase and vascular endothelial growth factor in human endometrial cells Endocrinology 145 4125-4133
[50] Meyer RK(2006)Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo J Am Coll Cardiol 47 1-8

← 1 2 3 4 5 6 7 8 9 10 →